Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001214659-25-003856
Filing Date
2025-03-04
Accepted
2025-03-04 17:04:12
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 14533
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 8511
3 EXHIBIT 99.2 ex99_2.htm EX-99.2 11058
  Complete submission text file 0001214659-25-003856.txt   35780
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
TANG CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001232621 (see all company filings)

EIN.: 461592449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Subject) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88628 | Film No.: 25706009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)